Aegerion Pharmaceuticals Expected To Take A Hit

By WM Analyst Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) won approval from the FDA for the drug JUXTAPID (lomitapide) capsules for Homozygous Familial Hypercholesterolemia, on ...

Gilead Seeks Blood Cancer Drugs to Bolster HIV Business

By Ryan Flinn Gilead Sciences Inc. (GILD), the world’s largest maker of HIV drugs, has spent $1.2 billion in two years to buy blood cancer drugs. It’s looking for more. Treatment ...

The Value Of A Pricey Orphan Drug: Nader Explains

By Ed Silverman Last month, the latest in a growing number of orphan drugs was approved by the FDA. And the Gattex treatment for short-bowel syndrome from NPS Pharmaceuticals (NPSP) ...

Too Late For Pharma: FTC Chair Leibowitz Is Leaving

By Ed Silverman After nearly four years as the head of the US Federal Trade Commission, Jon Leibowitz will be leaving the agency on February 15 (see the statement), and the news is ...

Pfizer, Zoloft And The Vexing Placebo Effect

By Ed Silverman In an unusual gambit, a California woman has filed a lawsuit claiming that the Zoloft antidepressant sold by Pfizer is no more effective than a placebo and that the ...

FDA stamps approval on Hyperion’s new orphan drug

By Ryan McBride Hyperion ($HPTX) has won its first FDA approval. The South San Francisco-based company grabbed the agency’s nod for its drug Ravicti, a treatment for managing ...

Gates-backed TB vaccine trial faces moment of truth

By Ryan McBride The global fight against tuberculosis is about to yield some big news. Next week researchers are reporting results of a mid-stage study of the leading next-generation ...

Gilead hungers for more cancer drug deals

By Ryan McBride Gilead Sciences ($GILD) waves an active trigger finger for acquisitions. After loading up on cancer drugs through a number of deals in recent years, the biopharma powerhouse ...

Bayer spotlights positive PhIII data for fat-busting drug

By Ryan McBride Bayer Healthcare touted upbeat data from a pair of late-stage studies of an investigational drug targeting chin fat, setting the stage for the giant to step into growing ...

GlaxoSmithKline shoots for combo attack against melanoma in surgery patients

By Ryan McBride GlaxoSmithKline ($GSK) has stepped up its late-stage program to advance a combo of targeted cancer drugs against deadly skin cancer, with a new study to see whether ...

Amgen to whack 160 jobs

Cuts come after mixed 4th quarter By Eric Palmer Amgen’s earnings last week were not half bad. But they were not good enough to save the jobs of 160 employees whom the company ...

Pfizer’s Zoetis spinoff outshines drug biz, at least for a day

Animal health unit catches investors’ attention By Eric Palmer The spinoff of Pfizer’s animal health unit has gone off with such success that it may make some wonder why CEO ...
Page 10 of 55« First...89101112...203040...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS